Rivaroxaban (Xarelto) is a type or oral anticoagulation medicine which is used to prevent blood clots following hip or knee surgery, for treatment and prevention of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and as a possible treatment to prevent stroke and blood clots embolism for people with Atrial Fibrillation, not caused by heart valve problems. Atrial Fibrillation is a condition that causes an irregular and often abnormally fast heart rate which disturbs the heart rhythm.
In 2009, NICE (National Institute for Health and Care Excellence) recommended Rivaroxaban as an option for prevention of venous thromboembolism in adults having elective total hip or total knee replacement surgery (TA 170)
In 2012, NICE recommended Rivaroxaban as an option for the prevention of stroke and and systemic embolism in people with non valular atrial fibrillation with one or more risk factors (TA 256)
In 2012, NICE recommended Rivaroxaban as an option for treating DVT and PE after a diagnosis of acute deep vein thrombosis in adults (TA 261)
In 2013, NICE recommended Rivaroxaban for acute symptomatic pulmonary embolism with or without symptomatic deep vein thrombosis and the prevention of recurrent VTE events (TA561)